Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 660.05
(-1.23%)
INR 660.05
(-1.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.6 Billion INR | 97.79% |
| 2022 | 3.34 Billion INR | 66.69% |
| 2021 | 2 Billion INR | -58.46% |
| 2020 | 4.82 Billion INR | 964760.0% |
| 2019 | -500 Thousand INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 6.58 Billion INR | 735.41% |
| 2024 Q1 | 795.9 Million INR | -87.95% |
| 2023 FY | 6.6 Billion INR | 97.79% |
| 2023 Q4 | 6.6 Billion INR | 1088.02% |
| 2023 Q2 | 7.18 Billion INR | 749.07% |
| 2023 Q1 | 845.9 Million INR | -74.68% |
| 2023 Q3 | 556.1 Million INR | -92.26% |
| 2022 Q2 | 3.34 Billion INR | 589.49% |
| 2022 Q1 | 485.3 Million INR | -75.78% |
| 2022 Q3 | 1.02 Billion INR | -69.41% |
| 2022 FY | 3.34 Billion INR | 66.69% |
| 2022 Q4 | 3.34 Billion INR | 226.32% |
| 2021 Q1 | 1.16 Billion INR | -75.83% |
| 2021 FY | 2 Billion INR | -58.46% |
| 2021 Q4 | 2 Billion INR | 185.04% |
| 2021 Q3 | 703 Million INR | -68.4% |
| 2021 Q2 | 2.22 Billion INR | 90.81% |
| 2020 FY | 4.82 Billion INR | 964760.0% |
| 2020 Q4 | 4.82 Billion INR | 964760.0% |
| 2020 Q3 | -500 Thousand INR | 0.0% |
| 2019 FY | -500 Thousand INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biocon Limited | 140.18 Billion INR | 95.287% |
| Blue Jet Healthcare Limited | -830.93 Million INR | 895.085% |
| Concord Biotech Limited | -54.04 Million INR | 12324.258% |
| Dishman Carbogen Amcis Limited | 18.99 Billion INR | 65.215% |
| Lyka Labs Limited | 527.01 Million INR | -1153.593% |
| Panacea Biotec Limited | -1.18 Billion INR | 657.566% |
| Piramal Pharma Limited | 42.27 Billion INR | 84.373% |
| SMS Lifesciences India Limited | 992.31 Million INR | -565.778% |
| Supriya Lifescience Limited | -694.68 Million INR | 1051.028% |
| Syngene International Limited | -83 Million INR | 8059.759% |
| TAKE Solutions Limited | 361.37 Million INR | -1728.209% |
| Zota Health Care Limited | 942.79 Million INR | -600.743% |